Orchestra BioMed priced 15 million shares of common stock at $5.00 late on November 5, for roughly $75M in gross proceeds before discounts and expenses. All the shares come from the company. The underwriters hold a 30-day option on 2,250,000 more. The offering is expected to close November 9.
Proceeds go to two pivotal programs. AVIM Therapy is a bioelectronic hypertension treatment delivered through a pacemaker, partnered with Medtronic for uncontrolled hypertension in pacemaker-indicated patients, and its BACKBEAT global pivotal trial has finished enrolling. Virtue SAB is an uncoated balloon that infuses an extended-release sirolimus formulation, and the Virtue Trial in coronary in-stent restenosis is still enrolling.
AVIM carries two FDA Breakthrough Device designations. Virtue SAB holds Breakthrough designations for coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. Piper Sandler and TD Cowen ran the book, with BTIG as bookrunner and H.C. Wainwright as lead manager.
Four banks on a $75M deal is a lot of hands for the size. It is also what carrying two pivotal trials on one balance sheet looks like when neither has a readout yet.